Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition

Keyphrases

• Heart Failure 100%
• Angiotensin-converting Enzyme Inhibition 100%
• Vasodilator 66%
• Angiotensin II (Ang II) 66%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 66%
• Clinical Efficacy 33%
• Quality of Life 33%
• Atrial Natriuretic Peptide 33%
• Congestive Heart Failure 33%
• Beta-blockers 33%
• Diagnostic Criteria 33%
• Patients with Heart Failure 33%
• Left Ventricular Dysfunction 33%
• Vasoconstriction 33%
• Ventricular Arrhythmia 33%
• Heart Failure Management 33%
• Left Ventricular Ejection Fraction 33%
• Pulmonary Edema 33%
• Adrenoceptors 33%
• Left Ventricular Function 33%
• Vasopressin 33%
• Exercise Intolerance 33%
• Pulmonary Congestion 33%
• Prolonged Life 33%
• Vasopressin Antagonists 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Enzyme Inhibition 100%
• Dipeptidyl Carboxypeptidase 100%
• Congestive Heart Failure 100%
• Dipeptidyl Carboxypeptidase Inhibitor 33%
• Angiotensin II 33%
• Syndrome 16%
• Atrial Natriuretic Factor 16%
• Lung Edema 16%
• Noradrenalin 16%
• Adrenergic Receptor 16%
• Heart Ventricle Arrhythmia 16%
• Heart Left Ventricle Failure 16%
• Lung Congestion 16%
• Vasopressin Antagonist 16%
• Vasopressin 16%